Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...

Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

While everyone is discussing are we in an AI bubble or not, Harvard is teaching how to invest in these irrational times.

Elon Musk's mega-deal combining SpaceX and xAI is the latest sign that the billionaire is consolidating his business empire ...

The Nasdaq Foundation's Economic Opportunity Grant Program drives impact through five key areas—regional revitalization and rural wealth building, access to capital, employee and community ownership, ...

Elon Musk's SpaceX has officially acquired another one of his companies, xAI. The technologist announced the deal in ...

The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...